Background: Risk prediction algorithms for coronary heart disease (CHD) are recommended for clinical use. However, their predictive ability remains modest and the inclusion of genetic risk may improve their performance. Methods: QRISK2 was used to assess CHD risk using conventional risk factors (CRFs). The performance of a 19 single nucleotide polymorphism (SNP) gene score (GS) for CHD including variants identified by genome-wide association study and candidate gene studies (weighted using the results from the CARDIoGRAMplusC4D metaanalysis) was assessed using the second Northwick Park Heart Study (NPHSII) of 2775 healthy UK men (284 cases). To improve the GS, five SNPs with weak evidence of an association with CHD were removed and replaced with seven robustly associated SNPs -giving a 21-SNP GS. Results: The weighted 19 SNP GS was associated with lipid traits (p < 0.05) and CHD after adjustment for CRFs, (OR = 1.31 per standard deviation, p = 0.03). Addition of the 19 SNP GS to QRISK2 showed improved discrimination (area under the receiver operator characteristic curve 0.68 vs. 0.70 p = 0.02), a positive net reclassification index (0.07, p = 0.04) compared to QRISK2 alone and maintained good calibration (p = 0.17). The 21-SNP GS was also associated with CHD after adjustment for CRFs (OR = 1.39 per
Introduction
While a large proportion of coronary heart disease (CHD) events are preventable [1, 2] , CHD remains a common cause of death worldwide. Therefore, identifying those at highest risk of developing the disease to target with lifestyle/therapeutic interventions is an important public health consideration. To take advantage of the combined knowledge of how conventional risk factors (CRFs) predispose individuals to CHD, risk scores have been developed. The first such score was derived from data collected as part of the prospective Framingham Study [3] -referred to as the Framingham score. While the score showed good predictive ability in some cohorts similar to that from which it was derived [4, 5] , it was found to overestimate risk in other ethnic groups [6] and in other populations of European ethnicity with a lower incidence of CHD [7, 8] . The development of primary care electronic records has enabled risk scores to be derived from large population cohorts. In England the QRISK score was derived from the QRESEARCH database, (which contains 1.2 million individuals) to estimate risk of cardiovascular disease (CVD) [9] and the most recent National Institute for Health and Clinical Excellence (NICE) guidelines recommend the most recent version of this tool (QRISK2) for clinical use [10] .
The majority of cases of CHD occur in individuals assigned with average risk using the CRF risk scores -the so-called prevention paradox [11] . When use of QRISK2 (2010 version) was validated with data from the health improvement network, 14% of men and 6% of women were identified as being at high risk (as determined by the guidelines at that time). This captured 40% of the cardiovascular events in men and 26% of the cardiovascular events in women [12] . This leaves scope for refinement of the risk score to discriminate between those who do and do not go on to develop CVD. In addition, the inclusion of a number of additional risk factors for CHD not currently included has been proposed such as inflammatory markers [13] , lipoprotein(a) [14] and genetic information.
It has so-far been unclear whether it is beneficial to include an estimate of genetic risk in CHD risk prediction. The Joint British Societies' consensus recommendations for the prevention of CVD (JBS3) concluded that the available evidence showed risk prediction tools including genetic information performed more poorly than CRF-based tools [15] . This has been underlined by the relatively disappointing performance of risk scores including gene scores (GSs) comprised of the variants identified in the CARDIoGRAMplusC4D meta-analysis of genome-wide association studies (GWASs) [16] . Assessment in the prospective Rotterdam study [17] and the University College, London School of Hygiene and Tropical Medicine, Edinburgh and Bristol (UCLEB) consortium data [18] found only a limited benefit in the populationwide inclusion of the GS in risk prediction, although improvements in both discrimination and reclassification were observed in a meta-analysis of six Swedish prospective cohorts [19] and the Malmo Diet and Cancer (MDC) study [20] .
In 2007 we started to develop a multi-single nucleotide polymorphism (SNP) panel using 12 SNPs in candidate genes that, when used in combination with the Framingham classical risk factor algorithm in a cohort of ~2700 middle-aged men from the UK (NPHSII), had the potential to identify individuals at high future risk of CHD [21] . We next showed that, in this same cohort, the addition of a single SNP from the first GWAS CHD locus identified on chromosome 9p21, improved the classical risk factor AROC by 3% but that this effect was not statistically significant [22] . By modelling, we estimated that an additional three SNPs with similar risk size and risk allele frequencies would be needed to have a significant improvement. We therefore developed a 19 SNP GS and found it to be of potential clinical utility in the same NPHSII cohort [23] . The GS comprised the 9p21 SNP plus six other GWAS loci identified at that time, supplemented by 12 common SNPs in candidate genes where published meta-analyses, mainly of case-control studies, had demonstrated robust albeit modest risk effects. The risk allele frequencies for these SNPs varied between 0.01 to 0.99 and the published odds ratios from 1.06-1.92 (see table 1  in Ref. 21 and Table 1 below) . However in the meta-analyses of large consortium data sets such as CARDIoGRAMplusC4D the odds ratios for several of the included SNPs had reduced and in some cases had become non-significant, and the use of these more robust risk estimates should improve the clinical utility of the gene score. In addition, replacing those SNPs which have non-significant CHD risk effects with SNPs with larger risk effects should also improve clinical utility.
Thus, the aim of this study was firstly to assess if the performance of the 19-SNP GS could be improved by updating its weightings, using the effect sizes derived from the CARDIoGRAMplusC4D GWAS meta-analysis [16] . Secondly, we sought to investigate the relationship between the updated gene score and CHD CRFs. Thirdly, we assessed the use of the combined CRF plus GS scores in CHD risk prediction to determine if including the 19-SNP GS could provide any additional clinical utility. Finally, we assessed if removing SNPs not found to be associated with CHD in the CARDIoGRAMplusC4D meta-analysis and replacing them with variants that were, improved its performance.
Materials and methods
The second Northwick Park heart study (NPHSII) NPHSII is a prospective CHD study of approximately 3000 men which has been described previously [26] . Briefly, middle-aged men (50-64) were recruited from nine general practices in the UK. Anyone with a history of CHD was excluded. There was a median of 13.5 years follow-up. CHD was defined as acute myocardial infarction (MI), silent MI or undergoing coronary surgery. Family history of early CHD was collected as reported previously [27] . All subjects gave written informed consent and the study had ethical approval from the national research ethics service (NRES) Committee London-Central. The baseline characteristics have been published previously by CHD outcome in follow-up [23] . The 2012 version of QRISK2 was calculated.
Genotyping
For the 19 SNPs previously genotyped and published [23] , some had been genotyped using restriction length polymorphism methods [21] but the majority of SNPs, as well as the seven SNPs added in this study, were genotyped using Taqman (Applied Biosystems, Life Technologies, Carlsbad, CA, USA) assays and KASPar (LGC. Teddington, Middlesex, UK) assays. The call rate for each genotype is listed in Table 1 .
Gene score
For the 19-SNP GS [23] , we updated the weightings to the beta-coefficients determined in the CARDIoGRAMplusC4D meta-analysis as previously described [28] . The values used are given in Table 1 . Three SNPs (rs7412 and rs429358 in APOE and rs11591147 in PCSK9) were not included in this analysis and the effect size from the most recent meta-analysis concerning the relationship between these SNPs and CHD was used as indicated. The SNPs included in both GSs are shown in Table 1 .
Statistical analysis
Use of an earlier version of the 19 SNP GS in NPHSII has been published [28] . We updated the weightings to the beta-coefficients determined in the CARDIoGRAMplusC4D meta-analysis as previously described [28] . Briefly, unweighted gene scores were determined by simply counting the number of risk alleles present for each SNP for each individual, while the weighted scores were calculated for each individual by multiplying the number of risk alleles carried for each SNP by the published effect size for that SNP and summing the values for all SNPs to obtain the individual's gene score. Numeric variables were compared using t-tests and categorical variables were compared using chi-squared tests. Regression was used to assess the relationship between the GS and CHD and CRFs. Calibration of the combined (CRF plus GS) risk scores was assessed with the HosmerLemeshow test (using 10 degrees of freedom). The ability of the risk scores to discriminate between those who did and did not have an event was assessed by comparing AUC values using DeLong's test. Reclassification of individuals into different risk categories with the addition of the GS to a CRF score was assessed using the net reclassification index (NRI). Where imputation was used, this was performed by assigning the missing genotype as the mean number of alleles for that particular SNP, only in those NPHSII participants with a single missing genotype. A p-value <0.05 was considered to be statistically significant. h In the original score, the protective allele was included rather than the risk allele. OR, odds ratio; Cplus4D, CARDIoGRAMplusC4D meta-analysis; CG GWAS, CARDIoGRAM GWAS.
Results

Baseline characteristics
The baseline characteristics of the NPHSII cohort are presented in Table 2 . As expected, men who developed CHD during follow-up were older, had higher BMI, systolic blood pressure, total cholesterol, low density lipoprotein (LDL) cholesterol, C-reactive protein (CRP) and fibrinogen and a higher proportion were smokers at baseline. Furthermore, those who developed CHD had a higher 10-year CHD risk as calculated using the Framingham score and those who developed CVD had a higher 10-year CVD risk as calculated using QRISK2.
Association of GS with CHD
The mean GS was higher in those who went to develop CHD and CVD during the 10-year follow-up, (Table 3) . Both the un-weighted and weighted GSs were associated with CHD after adjustment for age OR = 1.39 per standard deviation (SD) of GS [95% confidence intervals (CIs) 1.14-1.70 p = 1.37 × 10 
Association of GS with CRFs for CHD
The 19-SNP GS was associated with four lipid traits, cholesterol, LDL-cholesterol, apolipoprotein-B, and lipoprotein (a) (all p < 0.05) as shown in Table 3A . It was also associated with family history of CHD (p = 0.03), with 39% of these of the in top quartile of gene score having a family history of CHD compared to 31% in the bottom quartile.
The GS in CHD risk prediction
We assessed two CRF scores for CHD in NPHSII -the Framingham score and QRISK2. While QRISK2 was well calibrated (p = 0.10, Figure 1B , Figure 1A) . Therefore, further analysis was performed with QRISK2 only. Complete data (10-year CVD outcome, genotyping and QRISK2) was available for All variables are presented as the mean plus standard deviation except where indicated. Categorical variables were compared using chisquared tests and continuous variables were compared using Welch's t-tests, apart from the Lipoprotein (a), Framingham and QRISK2 risk scores (shown as proportions) which were compared using Mann-Whitney tests (the median and interquartile range are given). 1213 NPHSII participants for QRISK2 plus 19-SNP GS. This combined QRISK2 plus 19-SNP GS score remained well calibrated (p = 0.17, Figure 1B ) and showed an improvement in discrimination compared to QRISK2 alone (AUC 0.68 vs. 0.70 p = 0.02, Figure 2 ). The addition of the 19-SNP GS to QRISK2 also resulted in improved risk classification in the group who developed CHD, giving a positive NRI (NRI = 0.07, p = 0.04, Table 4 ).
Addition of extra SNPs
To assess if the gene score could be improved, we removed five SNPs which had shown little evidence of an association with CHD in the CARDIoGRAMplusC4D meta-analysis (p > 0.01) ( Table 1) . We then selected seven SNPs from those robustly associated with CHD in the CARDIoGRAMplusC4D. The SNPs were ranked according to risk allele Median and interquartile range shown and tobit regression on ln(lpa + 1). CHD, coronary heart disease; CRFs, conventional risk factors. Median and interquartile range shown and tobit regression on ln(lpa + 1).CHD, coronary heart disease; CRFs, conventional risk factors.
frequency multiplied by the beta-coefficient (Supplementary Table 1 ). The top seven SNPs, discounting those in loci already included in the GS (Table 1) , were then genotyped in NPHSII and added into the GS to create a 21 SNP GS.
The weighted 21-SNP GS was higher in those who went on develop CHD . As with the 19 SNP GS, the 21 SNP GS was associated with lipid traits, cholesterol, LDLcholesterol, and lipoprotein (a) (all p < 0.05) as shown in Table 3B .
When the 21-SNP GS was combined with QRISK2, this combined score remained well-calibrated (p = 0.11) and showed improved discrimination compared to QRISK2 alone (AUC 0.66 vs. 0.69, p = 0.04, Figure 2 ). However, while the NRI was positive, it was not statistically significant (NRI = 0.08, p = 0.10). One possibility for this could be loss of power due to sample drop-out, since only 954 participants had genotype data for all 21-SNPs as well as QRISK2 and follow-up data. To increase the number of participants that could be included in the analysis and as the data was considered to be missing at random, the missing genotype for those with only one missing genotype were imputed and the 21-SNP GS calculated.
In the imputed data set, the GS was similarly associated with CHD [OR = 1.38 per SD of GS (1.16-1.63) p = 1.31 × 10 −4 ] and remained so after adjustment for age, cholesterol, HDL-C, smoking, systolic blood pressure and family history of CHD, OR = 1.39 per SD of GS (1.14-1.71) p = 1.42 × 10 −3
. There was a significant association between the imputed 21-SNP GS and QRISK2 (p = 0.03), which was not the case with the un-imputed data set, (again probably reflecting the lower power in the unimputed data set). However, when the combined QRISK2 plus imputed 21-SNP GS score was calculated using this data (n = 1736) the score was poorly calibrated (p = 0.03) and did not show an improvement in discrimination (AUC 0.69 vs. 0.71, p = 0.55) or reclassification (NRI = 0.05, p = 0.10).
Discussion
In this study we assessed the relationship between a 19-SNP GS and CHD in a cohort of middle-aged men from the UK. The SNPs were originally chosen from meta-analyses of candidate gene studies and early GWASs [23] . In CRF, conventional risk factor; GS, gene score. meta-analyses of GWAS results based on >130,000 controls and >60,000 cases [16] which should provide a much more robust estimate of the effect size pertaining to each CHD risk loci than was previously available. Therefore the weightings used were updated to those effect sizes determined in the CARDIoGRAMplusC4D meta-analysis. A combined risk score of QRISK2 plus the updated 19-SNP GS was found to have good calibration and showed improved discrimination between those who did and did not develop CVD in follow-up and improved reclassification in those who developed CVD, compared to QRISK2 alone. Therefore, our results indicate that including this GS in an estimation of CHD risk could have clinical utility in the UK population. This result is likely to be relevant to subjects of similar ethnic origin such, but extension to other ethnic groups requires additional study.
Having improved the performance of the 19-SNP GS by updating its weightings, we then assessed a 21-SNP GS created from the 19-SNP GS. Five SNPs little evidence of an association with CHD in the CARDIoGRAMplusC4D metaanalysis were removed and replaced with the top seven ranked variants in loci not already included. Of these seven, three have are associated with blood pressure traits [GUCY1A3 (enzyme catalysing conversion of GTP to GMP, activated by nitric oxide) rs7692387, CYP17A1 (enzyme of the cytochrome P450 superfamily, involved in steroid biosynthesis) rs12413409, ZC3CH1 (protein involved in the regulation of mitosis) rs11556924] and one with lipid traits [LDLR (encodes the LDL receptor) rs1122608] [16] . It was expected that the addition of these robustly associated loci would more accurately reflect an individual's genetic risk of CHD and that further improve the performance of the combined QRISK2 plus GS risk score compared to QRISK2 alone. This appeared to be the case, although, possibly because of the reduced numbers available with complete genotype data, the NRI, which increased from 0.07 to 0.08, was not statistically significant. We expected that with increased numbers achieved by imputation of missing SNP data we would detect a statistically significant positive NRI and maintain good calibration while showing improved discrimination compared to QRISK2 alone. However, using the imputed data set, the combined QRISK2 plus imputed 21-SNP GS score showed poor calibration and no improvement in discrimination or NRI compared to QRISK2 alone. Further analysis found a statistically significant association between the 21-SNP GS and QRISK2 in the imputed data set, which was not observed in smaller un-imputed data set.
The results also show that QRISK2 was better at predicating cardiovascular outcome in NPHSII whereas the Framingham score overestimated risk in NPHSII. This is consistent with the literature where even the NICEadjusted Framingham risk equations have been found to overestimate 10-year CHD risk in the UK population, particularly in men [12] . The superior performance of QRISK2 compared to the Framingham score is unsurprising given that QRISK2 was derived from a very large British cohort while Framingham was developed from the Framingham Study based in Massachusetts, USA [3, 12, 29] .
The improved performance of the 19-SNP GS with the updated weightings (as detailed in [23] ) demonstrates that the effect sizes derived from the CARDIoGRAMplusC4D analysis more accurately reflect the impact of the SNPs CHD risk. All of the updated weightings were lower, indicating that the original effect sizes were inflated. This is a common problem in genetic studies [30] . However, it has been suggested that due to the nature of case selection in GWASs, many of the variants identified in the CARDIoGRAMplusC4D meta-analysis are actually associated with CHD survival rather than an incident CHD event itself. This is supported by data from both the Rotterdam Study and UCLEB consortium, where the GS was more strongly associated with prevalent rather than incident disease [17, 18] . This indicates that the weightings used may not accurately reflect the impact of each variant on incident CHD risk and thus effect sizes obtained from a prospective cohort should be used. This strategy was used by Ganna and colleagues and a better performance was observed with the inclusion of the GS [19] . This issue is likely to be more pertinent for the CARDIoGRAMplusC4D SNPs whereas the majority of SNPs included in the 19-SNP GS have a clear influence on CHD pathogenesis and rather than purely CHD survival. This may partly explain the relatively strong performance of the updated 19-SNP GSs in NPHSII compared to the relatively poor performance of the CARDIoGRAMplusC4D GSs in much larger studies. Ultimately, a large-scale well-powered prospective study is required to alleviate the problem of survival bias in genetic association studies. If such data became available, this could be used to provide the weights for the GS SNPs and this should improve its performance.
It not surprising that the 19-SNP GS is associated with a number of lipid traits, given that a number of SNPs in the GS are located in genes encoding proteins involved in lipid metabolism. The 19-SNP GS was associated with CHD even after adjustment for total cholesterol indicating that a higher 19-SNP GS value can reflect lifelong genetically raised total cholesterol, which confers a higher risk of CHD than can be reflected by a point measurement in later-life. Furthermore, the maintenance of the association between the 19-SNP GS and CHD despite the inclusion of the family history of CHD in the model suggests that these two related measures can provide information concerning different aspects of CHD risk.
This work has a number of limitations. One aim of our work is to identify a minimum SNP data set that will have clinical utility in CHD risk stratification. With more than 53 CHD SNPs now identified we chose to rank SNPs by the product of their European risk allele frequency and reported odds ratio, and examined the improvement achieved using only the top seven. While it is possible that the addition of SNPs who rank below these seven may improve clinical utility, the data suggest this improvement is at best likely to be modest, as demonstrated in the study using all 53 SNPs [18] . A second limitation is that all of the participants of NPHSII are male and with a mean age of 56 years represent a group where CHD is highly prevalent and where intervention to reduce future risk is recommended. It is known that the pathogenesis of atherosclerosis is different between the sexes [31] , but there is no evidence to suggest the risk variant effect sizes differ between men and women, and a subgroup analysis performed as part of the CARDIoGRAMplusC4D metaanalysis, found no trend for different odds ratios in either sex, but it would be ideal to test the GSs in a data set with both sexes. Another issue is that QRISK2 is updated annually and we did not have access to the most recent version, although the CRFs included are the same. Moreover, our cohort was recruited in 1989 and therefore the cardiovascular risk profile of this group may differ from that of the UK population now. Indeed, one of the reasons suggested for the overestimation of CHD risk by Framingham score is that the data it was derived from was collected at the time of peak cardiovascular risk in that community. However, this time-lag is inevitable in a prospective study and ultimately the benefits (particularly in minimising bias) outweigh the disadvantages.
The clinical utility of the GS described here depends on the context, as pointed out recently for T2D [32] . If a clinician is trying to ascertain the risk of 65-year-old men, the GS is irrelevant, since the vast majority will qualify for statin treatment under QRISK2 threshold set in the current NICE guidelines [33] . Conversely, at the age of 40 or even at birth the situation might be different. For example, at birth there will rarely be CRFs of concern but the GS can point much further in the future, suggesting that this individual might need to see a doctor when in their late thirties instead of past 40, as may otherwise be the case.
